Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical pharmacokinetics of fluvastatin.

C D Scripture1, J A Pieper

  • 1Division of Pharmacotherapy, School of Pharmacy, University of North Carolina, Chapel Hill 27599-7360, USA.

Clinical Pharmacokinetics
|May 23, 2001
PubMed
Summary

Fluvastatin, a synthetic HMG-CoA reductase inhibitor, effectively lowers cholesterol and prevents coronary events. It is metabolized in the liver with minimal drug interactions, though caution is advised with narrow therapeutic index drugs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacologic interventions for coronary artery disease and risk factors. Introduction.

Pharmacotherapy·2001
Same author

Management of coronary heart disease risk factors and progression with calcium channel blockers.

Pharmacotherapy·2001
Same author

Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.

Journal of clinical pharmacology·2001
Same author

Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients.

Journal of clinical pharmacology·2001
Same author

The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers.

Journal of clinical pharmacology·1999
Same author

Optimal management of amiodarone therapy: efficacy and side effects.

Pharmacotherapy·1998

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Fluvastatin is a synthetic HMG-CoA reductase inhibitor used for hyperlipidemia and coronary heart disease.
  • It is relatively hydrophilic, leading to extensive gastrointestinal absorption and hepatic metabolism.

Purpose of the Study:

  • To detail the pharmacokinetic profile of fluvastatin.
  • To investigate potential drug interactions with fluvastatin, particularly concerning cytochrome P450 enzymes.

Main Methods:

  • Analysis of fluvastatin absorption, distribution, metabolism, and excretion.
  • In vitro and in vivo studies to assess interactions with various drug classes, including CYP450 inhibitors and inducers, and gastrointestinal agents.

Main Results:

  • Fluvastatin is extensively metabolized in the liver to hydroxylated and N-desisopropyl metabolites, primarily excreted in bile.
  • CYP2C9 and CYP3A4 are involved in its metabolism; specific metabolites are exclusively formed by CYP2C9.
  • Fluvastatin has minimal extrahepatic distribution and its pharmacokinetics are not affected by renal function.
  • While CYP3A4 inhibitors do not affect fluvastatin, it inhibits CYP2C9, reducing the clearance of some substrates (diclofenac, tolbutamide) by 15-25%, though not clinically significant.
  • Interactions with warfarin and phenytoin require caution due to narrow therapeutic indices.

Conclusions:

  • Fluvastatin exhibits a favorable pharmacokinetic profile with limited interactions, primarily due to its hepatic metabolism and biliary excretion.
  • Its inhibitory effect on CYP2C9 warrants caution when coadministered with narrow therapeutic index CYP2C9 substrates like warfarin and phenytoin.

Related Experiment Videos